AC Immune SA (ACIU):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:AC Immune SA (ACIU) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7034
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥68,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥102,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AC Immune SA (AC Immune) is a biopharmaceutical company that develops products for treating neurodegenerative diseases. It discovers, designs and develops innovative proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms, SupraAntigen and Morphomer. These technology platforms aid in the design, discovery and development of antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate, crenezumab is an anti-Abeta antibody being developed in Phase III in collaboration with Genentech for treating Alzheimer’s disease. AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA (ACIU) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AC Immune SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
AC Immune SA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
AC Immune SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
AC Immune SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
AC Immune SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
AC Immune SA, Medical Equipment, Deal Details 10
Partnerships 10
AC Immune Enters into Partnership with Biogen 10
Nestle Institute of Health Sciences Enters into Research Agreement with AC Immune 11
AC Immune Enters into Research Agreement with Nestle Institute of Health Sciences 12
AC Immune Enters Into License Agreement With Piramal Imaging 13
Equity Offering 14
AC Immune Raises USD17.6 Million in Rights Offering of Shares 14
AC Immune Raises USD100 Million in Rights Offering of Shares 16
AC Immune Prices IPO for USD66 Million 18
AC Immune SA – Key Competitors 20
AC Immune SA – Key Employees 21
AC Immune SA – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 08, 2018: Ac Immune reports second quarter 2018 financial results and corporate update 23
May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update 25
Mar 20, 2018: AC Immune reports full-year 2017 financial results – successful first year as a public company 27
Nov 13, 2017: AC Immune Reports Third Quarter 2017 Financial Results and Corporate Update 30
Aug 09, 2017: AC Immune Reports Second Quarter 2017 Financial Results 32
May 11, 2017: AC Immune Reports First Quarter 2017 Financial Results 34
Mar 17, 2017: AC Immune Reports Full Year 2016 Financial Results and R&D Update 36
Product News 38
Feb 06, 2018: AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
AC Immune SA, Medical Equipment, Key Facts, 2017 2
AC Immune SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
AC Immune SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
AC Immune SA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
AC Immune SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
AC Immune SA, Deals By Market, 2012 to YTD 2018 8
AC Immune SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
AC Immune Enters into Partnership with Biogen 10
Nestle Institute of Health Sciences Enters into Research Agreement with AC Immune 11
AC Immune Enters into Research Agreement with Nestle Institute of Health Sciences 12
AC Immune Enters Into License Agreement With Piramal Imaging 13
AC Immune Raises USD17.6 Million in Rights Offering of Shares 14
AC Immune Raises USD100 Million in Rights Offering of Shares 16
AC Immune Prices IPO for USD66 Million 18
AC Immune SA, Key Competitors 20
AC Immune SA, Key Employees 21

List of Figures
AC Immune SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
AC Immune SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
AC Immune SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
AC Immune SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
AC Immune SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
AC Immune SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
AC Immune SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
AC Immune SA, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[AC Immune SA (ACIU):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Galen Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Galen Ltd (Galen), a subsidiary of Almac Group Ltd, is a pharmaceutical company. The company’s products include trustsaver, calceos, salivix, daunoxome, flotros, histofreezer, laxido, and saline steripoules, among others. It offers products in various therapy areas including angina, constipa …
  • Catalyst Paper Corporation:企業の戦略的SWOT分析
    Catalyst Paper Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Banco do Brasil SA:戦略・SWOT・企業財務分析
    Banco do Brasil SA - Strategy, SWOT and Corporate Finance Report Summary Banco do Brasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Apollo Consolidated Ltd (AOP):企業の財務・戦略的SWOT分析
    Summary Apollo Consolidated Ltd (Apollo), formerly Apollo Life Sciences Ltd, is a mining and mineral exploration company. The company’s business activities include acquisition, exploration, and development of gold, copper and nickel mineral deposits. It holds exploration permits in Western Australia …
  • Swan Life Ltd.:企業の戦略・SWOT・財務情報
    Swan Life Ltd. - Strategy, SWOT and Corporate Finance Report Summary Swan Life Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • PGE Polska Grupa Energetyczna SA (PGE)-エネルギー分野:企業M&A・提携分析
    Summary PGE Polska Grupa Energetyczna S.A. (PGE) is a state owned energy utility, which produces and supplies electricity in Poland. It carries out lignite mining activities, electricity generation from fossil fuels (lignite, hard coal and natural gas) and renewable energy sources (hydro, wind and b …
  • CIRFOOD Cooperativa Italiana di Ristorazione s.c.:企業の戦略・SWOT・財務情報
    CIRFOOD Cooperativa Italiana di Ristorazione s.c. - Strategy, SWOT and Corporate Finance Report Summary CIRFOOD Cooperativa Italiana di Ristorazione s.c. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Taisho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taisho Pharmaceutical Co Ltd (Taisho), a subsidiary of Taisho Pharmaceutical Holdings Co Ltd is a pharmaceutical company that develops, manufactures and markets a range of prescription pharmaceutical and self-medication drugs. The company offers products such as lipovitan D, riup, clarith, z …
  • Old National Bancorp:企業のM&A・事業提携・投資動向
    Old National Bancorp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Old National Bancorp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Tobu Railway Co Ltd:戦略・SWOT・企業財務分析
    Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Trammo Inc:企業の戦略的SWOT分析
    Trammo Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • MicroPort Scientific Corp (853)-医療機器分野:企業M&A・提携分析
    Summary MicroPort Scientific Corp (MicroPort) a subsidiary of Otsuka Medical Devices Co Ltd is a medical device company that develops, manufactures and markets cardiovascular treatment devices. The company provides products such as cardiovascular devices, orthopedic devices, endovascular devices, el …
  • Ashok Leyland Ltd (ASHOKLEY):企業の財務・戦略的SWOT分析
    Ashok Leyland Ltd (ASHOKLEY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • MorphoSys AG (MOR):企業の財務・戦略的SWOT分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, and research applications. The company’s pipeline products include MOR208, MOR103, MOR202, MAA868, VAY736, MOR106, and MOR107. Its drugs are used for the treatment of various types of cancers, psoriasis, rheuma …
  • Far East Hotels And Entertainment Limited:企業の戦略・SWOT・財務分析
    Far East Hotels And Entertainment Limited - Strategy, SWOT and Corporate Finance Report Summary Far East Hotels And Entertainment Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • KPC Pharmaceuticals Inc (600422)-製薬・医療分野:企業M&A・提携分析
    Summary KPC Pharmaceuticals Inc (KPC), formerly Kunming Pharmaceutical Corp, a subsidiary of Holley Group Co Ltd, is a manufacturer of botanical drugs and other pharmaceutical products. The company offers panax notoginseng, gastrodine, artemether and botanical drugs. It also offers drugs such as xue …
  • Handok Inc (002390)-医療機器分野:企業M&A・提携分析
    Summary Handok Inc (Handok), formerly known as Handok Pharmaceuticals Co Ltd, is a pharmaceutical and health care company which develops, manufactures and distributes healthcare solutions. The company develops and provides pharmaceutical products including prescription drugs, OTC drugs, medical devi …
  • Leprino Foods Co:企業の戦略的SWOT分析
    Leprino Foods Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • The E. W. Scripps Company:戦略・SWOT・企業財務分析
    The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report Summary The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • BioHorizons Inc-医療機器分野:企業M&A・提携分析
    Summary BioHorizons Inc (BioHorizons), a subsidiary of Henry Schein Inc is a medical device company that manufactures and develops dental products. The company’s products include dental implants, short implants, guided surgery kits, and others. It provides overdentures, gum grafting and bone graftin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆